Literature DB >> 18225596

Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth.

Kazutsugu Uematsu1, Nobuhiko Seki, Takashi Seto, Chie Isoe, Hideo Tsukamoto, Iwao Mikami, Liang You, Biao He, Zhidong Xu, David M Jablons, Kenji Eguchi.   

Abstract

BACKGROUND: We have previously found that Wnt signaling is activated in mesothelioma cells. To clarify the effect of blocking Wnt signaling in mesothelioma, the expression of dishevelled (Dvl), an intermediator of Wnt signaling, was down-regulated by a reformed type of small interfering RNA (siRNA), stealth RNAi, which can reduce the cytotoxic interferon response unlike conventional siRNA.
MATERIALS AND METHODS: Mesothelioma cell lines were transfected with stealth RNAi of Dvl, and cell growth and colony formation were examined. The synergistic effect on cell growth of Dvl stealth RNAi and cisplatin in combination was evaluated.
RESULTS: Dvl stealth RNAi down-regulated the expression of Dvl-3 in mesothelioma cells and induced cell cycle aberration which caused suppression of cell growth. Colony formation was also suppressed. Dvl stealth RNAi and cisplatin in combination suppressed cell growth synergistically.
CONCLUSION: Our data suggest that inhibition of Wnt signaling leads to significant antitumor effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18225596

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.

Authors:  Michele Carbone; Haining Yang
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

Review 2.  Drug development against the hippo pathway in mesothelioma.

Authors:  Gavitt A Woodard; Yi-Lin Yang; Liang You; David M Jablons
Journal:  Transl Lung Cancer Res       Date:  2017-06

Review 3.  Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.

Authors:  Ding-Wu Shen; Lynn M Pouliot; Matthew D Hall; Michael M Gottesman
Journal:  Pharmacol Rev       Date:  2012-06-01       Impact factor: 25.468

4.  Differences in gene expression profiles from asbestos-treated SPARC-null and wild-type mouse lungs.

Authors:  Mark A Pershouse; Aubrey M Smartt; Corbin Schwanke; Elizabeth A Putnam
Journal:  Genomics       Date:  2009-05-13       Impact factor: 5.736

Review 5.  Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

Authors:  Luciano Mutti; Tobias Peikert; Bruce W S Robinson; Arnaud Scherpereel; Anne S Tsao; Marc de Perrot; Gavitt A Woodard; David M Jablons; Jacinta Wiens; Fred R Hirsch; Haining Yang; Michele Carbone; Anish Thomas; Raffit Hassan
Journal:  J Thorac Oncol       Date:  2018-09       Impact factor: 15.609

6.  Synergistic effect of targeting dishevelled-3 and the epidermal growth factor receptor-tyrosine kinase inhibitor on mesothelioma cells in vitro.

Authors:  Gaku Moriyama; Maya Tanigawa; Kosuke Sakai; Yusuke Hirata; Satoshi Kikuchi; Yuriko Saito; Hiroyuki Kyoyama; Kuniko Matsuda; Masahiro Seike; Akihiko Gemma; Kazutsugu Uematsu
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

Review 7.  New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.

Authors:  Marika Rossini; Paola Rizzo; Ilaria Bononi; Anthony Clementz; Roberto Ferrari; Fernanda Martini; Mauro G Tognon
Journal:  Front Oncol       Date:  2018-04-03       Impact factor: 6.244

8.  SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma.

Authors:  Yi Zhang; Jianxing He; Fang Zhang; Hui Li; Dongsheng Yue; Changli Wang; David M Jablons; Biao He; Natalie Lui
Journal:  J Exp Clin Cancer Res       Date:  2013-02-05

9.  AMPK activators suppress cervical cancer cell growth through inhibition of DVL3 mediated Wnt/β-catenin signaling activity.

Authors:  H T Kwan; David W Chan; Patty C H Cai; Celia S L Mak; Mingo M H Yung; Thomas H Y Leung; Oscar G W Wong; Annie N Y Cheung; Hextan Y S Ngan
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

10.  Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease.

Authors:  Barbara Nuvoli; Sabrina Germoni; Carlotta Morosetti; Raffaela Santoro; Giancarlo Cortese; Serena Masi; Iole Cordone; Rossella Galati
Journal:  Mol Cancer       Date:  2014-03-21       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.